Feb 16 (Reuters) – British skin-health company SkinBioTherapeutics said on Monday it was investigating its former CEO and believes he misrepresented material financial information to the board and auditors.
The company said the resulting restatement of accounts would mean fiscal 2026 results would be “significantly below” market expectations.
(Reporting by Ankita Bora in Bengaluru; Editing by Rashmi Aich)
Brought to you by www.srnnews.com